TABLE 1.
Eight ustekinumab-modulated blood proteins in psoriasis are elevated to levels associated with future cardiovascular risk in the literature
| Protein | Fold change at baseline in psoriasis from control [equivalent percent increase] (p-value) | Fold change from baseline after treatment [equivalent percent decrease] (p-value) | Calculated % increase associated with CV risk in study | Study outcome | Study population |
|---|---|---|---|---|---|
| Myeloperoxidase (MPO) | 1.42 [42%] (0.06) |
−1.39 [39%] (0.02) |
10% | CAD development within 8 y | Apparently healthy men and women aged 40–79 without MI or stroke25 |
| C-X-C motif chemokine 10 (CXCL10) | 1.44 [44%] (0.04) |
−1.30 [30%] (0.03) |
34% | MI or SCD within 11 y | Men and women aged 35–74 without CHD39 |
| 26% | Ischemic stroke within 10 y | Asymptomatic men aged 50–59 without CAD or stroke44 | |||
| E-selectin (SELE) | 1.39 [39%] (0.04) |
−1.41 [41%] (0.01) |
22% | CVD event within 6 y | Type 2 diabetes patients of mean age 60.1 without CVD24 |
| Interleukin-6 (IL-6) | 1.95 [95%] (0.03) |
−1.56 [56%] (0.03) |
24% | MI within 6 y | Apparently healthy men aged 40–84 without CVD41 |
| Cystatin-B (CSTB) | 1.09 [9%] (0.55) |
−1.26 [26%] (0.05) |
7% | First MI or CHD related death within 14 y | Men and women aged 45–64 without CVD37 |
| von Willebrand factor (vWF) | 1.32 [32%] (0.20) |
−1.51 [51%] (0.01) |
12% | MI (fatal or non-fatal) within 5 y | Healthy men aged 50–59 with no previous CHD events20 |
| Tumor necrosis factor receptor 1 (TNF-R1) | 1.16 [16%] (0.14) |
−1.17 [17%] (0.05) |
14% | CHD within 8 y | Men and women aged 30–75 without CVD38 |
| N-terminal prohormone brain natriuretic peptide (NT-proBNP) | 1.42 [42%] (0.06) |
−1.37 [37%] (0.03) |
37% | First major CVD event within 5 ya | Men and women aged 30–59 without CVD36 |
The percent increases in protein levels of the psoriasis cohort at baseline were compared to the calculated percent increase in protein levels associated with future CV risk in the literature. Eight proteins were elevated in the psoriasis cohort at baseline by a percent increase that was above the percent increase associated with CV risk, and were significantly down-regulated after 12 weeks of ustekinumab treatment.
Abbreviations: AP, angina pectoris; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction; SCD, sudden cardiac death; y, year.
This study measured BNP levels, which have been shown to correlate linearly with NT-proBNP.47